135 related articles for article (PubMed ID: 38451491)
61. Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
Elbanna M; Shiue K; Edwards D; Cerra-Franco A; Agrawal N; Hinton J; Mereniuk T; Huang C; Ryan JL; Smith J; Aaron VD; Burney H; Zang Y; Holmes J; Langer M; Zellars R; Lautenschlaeger T
Clin Lung Cancer; 2021 May; 22(3):e342-e359. PubMed ID: 32736936
[TBL] [Abstract][Full Text] [Related]
62. Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
Radiother Oncol; 2021 Mar; 156():153-159. PubMed ID: 33333139
[TBL] [Abstract][Full Text] [Related]
63. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P
BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805
[TBL] [Abstract][Full Text] [Related]
64. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
[TBL] [Abstract][Full Text] [Related]
65. Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer.
Verma V; Simone CB; Allen PK; Gajjar SR; Shah C; Zhen W; Harkenrider MM; Hallemeier CL; Jabbour SK; Matthiesen CL; Braunstein SE; Lee P; Dilling TJ; Allen BG; Nichols EM; Attia A; Zeng J; Biswas T; Paximadis P; Wang F; Walker JM; Stahl JM; Daly ME; Decker RH; Hales RK; Willers H; Videtic GM; Mehta MP; Lin SH
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):362-371. PubMed ID: 28011047
[TBL] [Abstract][Full Text] [Related]
66. The management of stage I Non-Small cell lung cancer (NSCLC) in Ontario: A Population-Based study of patterns of care and Stereotactic Ablative Body radiotherapy (SABR) utilization from 2010 to 2019.
Ashworth A; Kong W; Owen T; Hanna TP; Brundage M
Radiother Oncol; 2024 May; 194():110153. PubMed ID: 38364940
[TBL] [Abstract][Full Text] [Related]
67. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
68. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
[TBL] [Abstract][Full Text] [Related]
69. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
Mahmood S; Bilal H; Faivre-Finn C; Shah R
Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381
[TBL] [Abstract][Full Text] [Related]
70. Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life.
Jain S; Poon I; Soliman H; Keller B; Kim A; Lochray F; Yeung L; Cheung P
Radiother Oncol; 2013 Aug; 108(2):320-5. PubMed ID: 23993401
[TBL] [Abstract][Full Text] [Related]
71. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
Abel S; Hasan S; White R; Schumacher L; Finley G; Colonias A; Wegner RE
Lung Cancer; 2019 Feb; 128():127-133. PubMed ID: 30642444
[TBL] [Abstract][Full Text] [Related]
72. Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis.
Lee TH; Kim DY; Wu HG; Lee JH; Kim HJ
Radiat Oncol; 2021 Nov; 16(1):222. PubMed ID: 34794471
[TBL] [Abstract][Full Text] [Related]
73. Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiation Therapy for Non-Small Cell Lung Cancer.
Devine M; Merriott DJ; No HJ; Lau B; Say C; Yoo C; Yi E; Ko RB; Neal JW; Wakelee HA; Das M; Loo BW; Diehn M; Chin AL; Vitzthum LK
Pract Radiat Oncol; 2023; 13(1):e35-e44. PubMed ID: 35858658
[TBL] [Abstract][Full Text] [Related]
74. Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors.
Moding EJ; Liang R; Lartey FM; Maxim PG; Sung A; Diehn M; Loo BW; Gensheimer MF
Clin Lung Cancer; 2019 Nov; 20(6):461-468.e2. PubMed ID: 31377143
[TBL] [Abstract][Full Text] [Related]
75. Treatment completion, treatment compliance and outcomes of old and very old patients treated by dose adapted stereotactic ablative radiotherapy (SABR) for T1-T3N0M0 non-small cell lung cancer.
Mihai A; Milano MT; Santos A; Kennedy A; Thirion P; McDermott RS; Westrup J; Rock L; Armstrong J
J Geriatr Oncol; 2019 May; 10(3):442-448. PubMed ID: 30420322
[TBL] [Abstract][Full Text] [Related]
76. MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial.
Timmer FEF; Geboers B; Ruarus AH; Vroomen LGPH; Schouten EAC; van der Lei S; Vos DJW; Dijkstra M; Schulz HH; Bakker J; van den Bemd BAT; van den Tol PM; Puijk RS; Lissenberg-Witte BI; de Gruijl TD; de Vries JJJ; Lagerwaard FJ; Scheffer HJ; Bruynzeel AME; Meijerink MR
Lancet Gastroenterol Hepatol; 2024 May; 9(5):448-459. PubMed ID: 38513683
[TBL] [Abstract][Full Text] [Related]
77. Never too old: A single-institution experience of stereotactic body radiation therapy for patients 90 years and older with early stage lung cancer.
Videtic GMM; Woody NM; Reddy CA; Stephans KL
Pract Radiat Oncol; 2017; 7(6):e543-e549. PubMed ID: 28867545
[TBL] [Abstract][Full Text] [Related]
78. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
[TBL] [Abstract][Full Text] [Related]
79. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
Palma DA; Olson R; Harrow S; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman GS; Warner A; Senan S
Lancet; 2019 May; 393(10185):2051-2058. PubMed ID: 30982687
[TBL] [Abstract][Full Text] [Related]
80. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
